glp.1 Glucagon-like peptide-1 Bariatric Fusion GLP Nature Made GLP-1 Companion Health

doi: 10.1210/en.2014-1675 52 AlvarezEMartinezMDRonceroIChowenJAGarcia-CuarteroBGispertJDet al

This article examines the current evidence, biological mechanisms, and clinical implications of GLP-1 receptor agonists in relation to cognitive function and dementia risk

persistent, severe abdominal pain) Hypersensitivity to DPP-4 inhibitors in the past Pregnancy/breastfeeding Some DPP-4 inhibitors are contraindicated at certain thresholds of renal impairment (see Table 2 ) Some DPP-4 inhibitors are contraindicated in hepatic impairment (see Table 3 ) Type 1 diabetes Diabetic ketoacidosis Cautions History of pancreatitis Moderate heart failure (saxagliptin only, due to limited experience) Severe heart failure (saxagliptin and vildagliptin, due to limited experience) Some DPP-4 inhibitors are cautioned at certain thresholds of renal impairment, and dose reductions may be required (see Table 2 ) Drug interactions No significant interactions have been reported between DPP-4 inhibitors and any other drugs

78 The average half-life of exenatide is 2.4 h, 2 to 3 times per day

The combination of GLP-1 and GIP activation is what makes tirzepatide produce faster and more significant results than single-target GLP-1 medications